Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

1.5K
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.5K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

804
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
804
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

421
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
421
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.4K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

3.1K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
3.1K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

956
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
956

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotoxicity Studies of Milk Thistle Fruit (Silybum marianum fructus) Dry Extracts: No Hints of Mutagenicity.

Planta medica·2026
Same author

Transcriptome analysis of classical blood cells reveals downregulation of pro-inflammatory genes in the classical monocytes of long COVID patients.

Frontiers in immunology·2025
Same author

Genotoxicity Assessment of Hypericum perforatum Dry Extracts in the Ames Test Based on the "Bracketing and Matrixing" Concept.

Planta medica·2025
Same author

Rationalising Optimal Dosing of Phytotherapeutics For Use In Children: Current Status - Potential Solutions - Actions Needed.

Planta medica·2024
Same author

Consensus Statement on the Outcome of a Workshop on Paediatric Phytotherapy: Rationalising Optimal Dosing for Use in Children by Real-World Data.

Planta medica·2023
Same author

Phytomedicine ELOM-080 in Acute Viral Rhinosinusitis: A Randomized, Placebo-Controlled, Blinded Clinical Trial.

The Laryngoscope·2022

Related Experiment Video

Updated: Apr 26, 2026

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.2K

Valerian: no evidence for clinically relevant interactions.

Olaf Kelber1, Karen Nieber2, Karin Kraft3

  • 1Working Group Efficacy, Safety and Interactions of Kooperation Phytopharmaka GbR, Plittersdorfer Straße 218, 53173 Bonn, Germany ; Medical Information and Clinical Research, Steigerwald Arzneimittelwerk GmbH, 64295 Darmstadt, Germany.

Evidence-Based Complementary and Alternative Medicine : Ecam
|August 6, 2014
PubMed
Summary

Valerian root preparations appear safe for cancer patients, with low interaction potential with anticancer drugs. Scientific evidence does not support claims of adverse effects, confirming its safety for this population.

More Related Videos

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.9K

Related Experiment Videos

Last Updated: Apr 26, 2026

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.2K
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.9K

Area of Science:

  • Pharmacology
  • Herbal Medicine
  • Oncology

Background:

  • Popular media and websites claim valerian root may interact adversely with anticancer drugs.
  • This raises concerns about valerian's safety as a substitute for medications like benzodiazepines.
  • A comprehensive review was needed to assess valerian's interaction potential.

Purpose of the Study:

  • To systematically review the interaction potential of Valeriana officinalis L. root preparations.
  • To evaluate the clinical relevance of reported in vitro and in vivo interactions.
  • To determine the safety of valerian use in cancer patients.

Main Methods:

  • Conducted a database search and a clinical drug interaction database search.
  • Performed a systematic assessment of identified publications.
  • Reviewed in vitro studies on CYP 450, p-glycoprotein, and UGT isoenzymes.
  • Analyzed clinical studies and pharmacodynamic data in animals and humans.

Main Results:

  • Seven in vitro studies were identified, but their methodology was insufficient for predicting clinical relevance.
  • Clinical studies showed no relevant interactions with key cytochrome P450 enzymes (CYP 1A2, 2D6, 2E1, 3A4).
  • Animal and human pharmacodynamic studies did not confirm any significant interaction potential.

Conclusions:

  • The interaction potential of valerian preparations appears low and clinically irrelevant.
  • There is no specific evidence to question the safety of valerian, even for cancer patients.
  • Valerian can be considered safe for use, including in oncology settings.